Nephrolyx

📍 Berlin, Germany🗓 Founded 2021👥 11 employees💰 Last funded May 2023
Biotechnology Research🌐 nephrolyx.com
Website LinkedIn
Nephrolyx offers a precise and rapid measurement of the kidney function (true GFR). We provide hospitals and laboratories with an In-Vitro Diagnostic Test and a digital platform to measure the true GFR within only a few hours. For the first time, physicians can detect renal diseases using the highest accuracy of GFR measurement and adapt an optimal treatment plan for patients. Especially nephrology, oncology, transplantation, and ICU patients can benefit from rapid and precise diagnostics. The Nephrolyx IVDx is indicated for the in-vitro quantitative determination of serum iohexol concentration and calculation of the glomerular filtration rate (GFR). The principle of the test is based on Ultra-High-Performance-Liquid Chromatography using Ultra-Violet light. Proprietary technology from Nephrolyx helps to improve treatment success for kidney patients. Given its low component cost, the Nephrolyx IVDx can also significantly enhance the performance of the entire healthcare system.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
3
Investor activity2022–2023 · investors recorded per year
2022120232
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nephrolyx?
Nephrolyx has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Nephrolyx last raise funding?
The most recent investment in Nephrolyx recorded on gritt.io was in May 2023.
When was Nephrolyx founded?
Nephrolyx was founded in 2021.
What industry is Nephrolyx in?
Nephrolyx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nephrolyx based?
Nephrolyx is headquartered in Berlin, Germany.